Short-term exposure of sleep deprivation male model rats to dutasteride promotes the discovery of gene profiles related to fertility impairments. [PDF]
BMC Med GenomicsZhang S, Li W, Zhang G.
europepmc +1 more source
Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report. [PDF]
Case Rep DermatolElhaj H, Orrell KA, Beach RA.
europepmc +1 more source
Direct No-Shave Follicular Unit Excision (DNS FUE): A Modified Technique and Case Series. [PDF]
CureusBrigante R, Wells A.
europepmc +1 more source
Response to the letter to the editor: Body mass index as a potential confounder in dutasteride and fertility studies. [PDF]
Clin Exp Reprod MedKim YJ, Lee SR, Yu YD.
europepmc +1 more source
Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting. [PDF]
Pharmaceuticals (Basel)Małkowski M +4 more
europepmc +1 more source
Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System. [PDF]
Int J DermatolGupta AK +3 more
europepmc +1 more source
Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over-the-Counter Products for Male Androgenetic Alopecia: A Network Meta-Analysis Study. [PDF]
J Cosmet DermatolGupta AK, Bamimore MA, Talukder M.
europepmc +1 more source
Related searches:
Dutasteride in Androgenetic Alopecia: An Update
Current Clinical Pharmacology, 2017Androgenetic alopecia is a common condition characterized by thinning of scalp hair. Conversion of testosterone to dihydrotestosterone, a more potent androgen, by the enzyme 5-α-reductase is responsible for underlying pathogenesis. Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type-1 and type-2 isoenzymes of 5 ...
Tasleem Arif +2 more
exaly +3 more sources
Dutasteride, a potent inhibitor of type 1 and 2 5alpha-reductase, reduced dihydrotestosterone levels by >90% in 85% of patients following 1 years' administration of oral dutasteride 0.5 mg/day. A combined analysis of three placebo-controlled clinical studies conducted in patients with benign prostatic hyperplasia (BPH) found sustained improvements in ...
Hannah C, Evans, Karen L, Goa
+7 more sources
The Cardiovascular Safety of Dutasteride
Journal of Urology, 2017Randomized controlled trials suggest an increased risk of heart failure with dutasteride, which inhibits both the type 1 and type 2 isoforms of 5α-reductase. In contrast, no such association has been suggested for finasteride, which selectively inhibits the type 2 isoform.
Sean C, Skeldon +6 more
openaire +2 more sources